Check 35,000+ stocks against 26 valuation models and 37 quality factors

CONMED Corporation (CNMD) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of CONMED Corporation $34.56, price $45.80, upside -24.5%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Healthcare · US · ISIN US2074101013

Broad data Sep 23, 2026

CONMED Corporation

CNMD · US

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value $34.56 · Overvalued (−25%)

!Quality 53/100

✓Healthy Growth (revenue 5y +9.8 %/yr)

!Thin margins · 4.0% net margin (TTM)

✓Moderate debt · generates free cash flow

·0.87% dividend yield

!Mixed vs. peers (7/15)

!Narrow moat 38/100

!Weak on valuation: 1 out of 100

!Weak on past: 22 out of 100

!Weak on dividend: 17 out of 100

26 models, one by oneBear $22.71 to bull $52.84 Growth analysisrevenue history, year by year Quality 53/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch CONMED Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $32.11 – $151.17 · fair‑value band $22.71 – $52.84 · the $45.80 price screens above the $34.56 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 23, 2026.

Follow CONMED in your weekly email

Every Wednesday you see whether CONMED is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures.

CONMED Corporation, a medical technology company, develops, manufactures, and sells devices and equipment for surgical procedures. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as supporting products include powered resection instruments , fluid management, and visualization systems and the related single-use products that enable surgeons to perform minimally invasive sports medicine surgeries. It also provides battery-powered, autoclavable, large, and small bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under the Hall surgical brand name. In addition, the company offers general surgery products, such as clinical insufflation systems under the AirSeal brand; smoke removal devices under the Buffalo Filter brand; endomechanical products, including the Anchor1 line of tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors, used in minimally invasive surgeries; and electrosurgical solution comprise monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems, and other accessories. Further, it provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products to treat diseases of dilation, hemostasis, biliary, stricture management, infection prevention, and patient monitoring include ECG electrodes, EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. The company was incorporated in 1970 and is headquartered in Largo, Florida.

Stock analysis

CONMED Corporation (CNMD) currently trades at $45.80, while our model-based Fair Value estimate is $34.56, implying the stock looks roughly 32.5% overvalued today.

Valuation

Bull case: the Growth DCF group reads highest at a median of $46.28 per share, and 8 of the 26 models we run sit above the $45.80 price.

Bear case: the Economic Profit group reads lowest at $9.00, and 18 of the 26 models stay below the price. Evidence for this calculation is high.

Scenario range: $22.71 (bear) to $52.84 (bull), the price of $45.80 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

CONMED Corporation reported revenue of $1.4B in FY2025 versus $1.0B in FY2021, a compound +8.0%/yr. Reported net income was $47.1M in FY2025, compounding −6.9%/yr from FY2021.

Key figures

Market cap $1.4B · P/E ratio 25.9 · P/S ratio 0.89 · EPS (TTM) $1.77 · Dividend yield 0.9% · Net margin 3.4% · Return on equity 5.5% · Return on assets (EBIT) 5.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 12% below its 52-week high and 43% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −25%, CNMD screens richer than that median.

Fair Value models

Bear $22.71 Fair Value $34.56 Bull $52.84

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($1.00 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF $30.23 $58.09 $96.42 78

Growth DCF $30.32 $54.06 $84.43 77

Residual Income $24.56 $24.26 $21.18 76

All 26 models by family

DCF Models

FCF DCF $30.23 $58.09 $96.42 78

Owner Earnings $14.43 $34.50 $62.13 72

5Y Revenue Exit $20.59 $45.97 $78.21 69

5Y EBITDA Exit $36.46 $76.29 $123.24 73

5Y P/E Exit $9.84 $25.44 $41.57 68

10Y Revenue Exit $22.74 $45.79 $76.73 64

10Y EBITDA Exit $33.19 $65.25 $108.74 66

10Y P/E Exit $17.54 $32.62 $50.67 62

Earnings-Based

Graham-Dodd $10.63 $36.70 $49.30 64

Lynch FV $8.49 $12.13 $15.77 61

PEG = 1.0 $8.49 $12.13 $15.77 57

EPV $4.75 $9.00 $12.53 71

Dividend Discount

Gordon GGM $6.39 $11.51 $15.84 68

DDM Multi-Stage $6.39 $10.41 $12.29 67

Multiples

P/E Multiple $25.79 $34.38 $42.98 63

P/S Multiple $19.93 $26.57 $33.21 58

P/B Multiple $19.93 $26.57 $33.21 55

EV/EBIT $33.41 $53.33 $73.25 64

EV/EBITDA $48.77 $73.81 $98.85 66

EV/Revenue $16.30 $34.58 $52.86 51

Asset-Based

NCAV (Graham) $17.16 $22.99 $34.31 54

Growth DCF

Growth DCF $30.32 $54.06 $84.43 77

Rev-Margin DCF $20.59 $46.28 $76.80 70

Economic Profit

Residual Income $24.56 $24.26 $21.18 76

ROIC Compounder $4.75 $9.00 $12.53 70

Growth Earnings

Growth-Adj P/E $22.01 $31.44 $40.87 67

Open the full fair value analysis →

Notify me when CNMD reaches fair value

Put CNMD on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 53/100

Of which business quality 52 · Market factors (momentum, volatility) 56

Profitability 35

Margins and returns on capital today

Quality Growth 25

Are margins and returns improving?

Cashflow 73

Earnings quality: real cash, not paper profit

Fin. Strength 38

Balance sheet, leverage, solvency risk

Investment 80

Disciplined investing over empire-building

Low Volatility 51

Calm price path (market factor)

Momentum 64

Price trend over the last 3–12 months (market factor)

52W Momentum 47

Distance to the 52-week high (market factor)

Net Issuance 75

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 80/100

Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Revenue growth 1 year

+5.2%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+9.5%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+9.8%

Start year 2020 (pandemic). Over 10 years: +6.7% a year

Revenue growth 39 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+13.3%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.

+14.7%

Earnings growth per share plus dividend.

Earnings per share, growth per year+13.8%

Dividend (yield on the price)0.9%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.9% vs 3%, picking up

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.5% → 10%

Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price

The price assumes about as much growth as the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+6.9%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+3.7%

Yearly sales growth analysts expect, extended to five years.

After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +4.4% a year for the price and +1.3% for the forecasts.

Forecast 2026 (sales)−0.9%

Forecast 2027 (sales)+5.5%

Projected 2028 (sales)+5.1%

Projected 2029 (sales)+4.6%

Projected 2030 (sales)+4.2%

CNMD screens 33% overvalued. Compare with Abbott Laboratories, →

Compare CONMED Corporation with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 361 stocks

Beats the industry median on 6/14 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 53 · Above median

Fair Value upside −25% · Below median

Profitability

Return on equity (TTM) 6% · Above median

Return on assets 4% · Above median

Net margin (TTM) 4% · Below median

Operating margin (TTM) 10% · Above median

Growth and dividend

Revenue growth −1% · Below median

Dividend yield (TTM) 0.9% · Bottom 25%

Balance sheet

Debt / equity 0.81× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (TTM) 25.9× · Pricier than median

P/B 1.38× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.

P/S (TTM) 1.04× · Cheaper than median

P/FCF 9.5× · Pricier than median

EV/EBITDA 10.5× · Cheaper than median

PEG 1.84× · Pricier than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)1 · sector 11

FUTURE (revenue growth)0 · sector 31

PAST (return on equity)22 · sector 8

HEALTH (low debt)60 · sector 97

DIVIDEND (yield)17 · sector 40

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Abbott Laboratories, ABT	$103.69	$74.79	−28%
Stryker Corporation SYK	$275.09	$302.60	+10%
Medtronic plc MDT	$90.77	$65.57	−28%
Boston Scientific Corporation BSX	$44.92	$49.41	+10%
Edwards Lifesciences Corporation EW	$88.78	$82.04	−8%
Siemens Healthineers AG SHL	€37.43	€35.22	−6%
DexCom, Inc DXCM	$89.53	$98.48	+10%
GE HealthCare Technologies Inc GEHC	$66.27	$69.62	+5%
Shenzhen Mindray Bio-Medical Electronics Co 300760	¥156.68	¥172.35	+10%
Koninklijke Philips N.V PHIA	€21.85	€15.32	−30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CONMED Corporation · Fair Value
$34.56 −33%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/CNMD" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">CONMED Corporation · Fair Value</span><br><b style="font-size:20px">$34.56</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−33%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "CONMED Corporation Fair Value". https://www.fairvalue-calculator.com/stock/CNMD

Frequently asked questions

Is CONMED Corporation (CNMD) overvalued or undervalued?

As of Sep 23, 2026, our model estimates a fair value of $34.56 versus a price of $45.80, about −25% upside (overvalued).

What is the fair value of CNMD?

Our model-based fair value for CONMED Corporation is $34.56 (as of Sep 23, 2026), built from audited fundamentals. The current price: $45.80.

What is the quality score of CNMD?

CONMED Corporation has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for CONMED Corporation (CNMD)?

Our model-based price target is the fair value of $34.56 (as of Sep 23, 2026) from 26 valuation models. Cautious scenario $22.71, optimistic scenario $52.84. It is a calculation from audited fundamentals, not an analyst target.

What is the CONMED Corporation stock forecast for 2026?

Our models put fair value at $34.56, about −25% upside versus a price of $45.80 (overvalued). Cautious scenario $22.71, optimistic scenario $52.84. The calculation is refreshed regularly with new filings.

What is the revenue of CONMED Corporation (CNMD)?

CONMED Corporation reported trailing-twelve-month revenue of about $1.4B (latest available figure, as of Sep 23, 2026).

Does CONMED Corporation pay a dividend?

CONMED Corporation currently shows a dividend yield of about 0.87% relative to its recent price (as of Sep 23, 2026).

What growth is priced into CONMED Corporation (CNMD)?

For today's price to be fair in a discounted-cash-flow model, CONMED Corporation would have to grow free cash flow by +6.9 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.8 % per year. As of Sep 23, 2026.

What discount rate (WACC) does the fair value of CNMD use?

Our models discount CONMED Corporation at 11.0 %: a base by market capitalisation (small), damped by beta 0.92, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For CONMED Corporation that is +6.9 % per year a year over ten years, using the same discount rate (11.0 %) and the same formula as our fair value.

How much growth has CONMED Corporation (CNMD) delivered so far?

Over the past 5 years revenue at CONMED Corporation grew +9.8 % a year. The price currently implies +6.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of CONMED Corporation (CNMD) growing?

The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into CONMED Corporation (+6.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of CONMED Corporation (CNMD)?

The free-cash-flow yield on the price is 10.58 %: that much free cash flow CONMED Corporation produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of CONMED Corporation (CNMD)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CONMED Corporation it is $34.56 per share (as of Sep 23, 2026), against a price of $45.80. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is CONMED Corporation stock overvalued or undervalued in 2026?

As of Sep 23, 2026, CNMD trades above its calculated fair value: price $45.80, fair value $34.56, a gap of about −25% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of CNMD?

No. The price is what the market pays today ($45.80); the fair value is what the company's own numbers justify ($34.56). For CONMED Corporation the two are $11.24 per share apart. That gap is exactly why we show both numbers side by side.

How much is CONMED Corporation worth?

The market values CONMED Corporation at about $1.4B (market capitalisation, as of Sep 23, 2026). Per share that is $45.80; our models calculate a fair value of $34.56 per share.

What do the bullish and bearish scenarios say about CNMD?

Our models span a range for CONMED Corporation: cautious scenario $22.71, base $34.56, optimistic $52.84 per share (as of Sep 23, 2026, price $45.80). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of CNMD?

CONMED Corporation trades at a price-to-earnings ratio of 25.9 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $34.56 is built from several models across several years. Other multiples: PEG 1.8, P/B 1.4, P/S 1.0, EV/EBITDA 10.5.

What is the PEG ratio of CNMD?

The PEG ratio of CONMED Corporation is 1.84 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.

How solid is the balance sheet of CONMED Corporation (CNMD)?

Balance-sheet figures for CONMED Corporation (as of Sep 23, 2026): return on equity 5.5%, debt of 0.81 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.

How far is CNMD from its 52-week high?

CONMED Corporation trades at $45.80, about 12% below its 52-week high of $51.86 and 43% above the low of $32.11 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $34.56 is for.

Which stocks are comparable to CONMED Corporation?

From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is CONMED Corporation stock attractive at the current price?

The data as of Sep 23, 2026: price $45.80, calculated fair value $34.56 (−25%), Quality Score 53/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of CNMD calculated?

We run CONMED Corporation through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $34.56, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.1 % above its aggregate fair value. CONMED Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of CONMED Corporation (CNMD)?

The closing price on Sep 23, 2026 was $45.80. Our model-based fair value is $34.56, about −25% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with CONMED Corporation right now?

Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($22.71 to $52.84) leaves room in how you read the outcome.

Where does the earnings growth of CONMED Corporation (CNMD) come from?

Earnings per share at CONMED Corporation grew +12.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share +5.2 %, EBIT margin +7.0 %, tax rate +1.2 %, residual (interest, one-offs) −1.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of CONMED Corporation

How large is the market capitalisation of CONMED Corporation (CNMD)?

The market capitalisation of CONMED Corporation is $1.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of CONMED Corporation (CNMD)?

The price-to-sales ratio of CONMED Corporation is 0.89 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of CONMED Corporation (CNMD)?

Earnings per share at CONMED Corporation are $1.77 (price ÷ EPS = P/E 25.9). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of CONMED Corporation (CNMD)?

The dividend yield of CONMED Corporation is 0.9% (payout 22.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of CONMED Corporation (CNMD)?

The net margin of CONMED Corporation is 3.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of CONMED Corporation (CNMD)?

The return on equity (ROE) of CONMED Corporation is 5.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of CONMED Corporation (CNMD)?

On an EBIT basis the return on assets of CONMED Corporation is 5.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of CONMED Corporation (CNMD)?

The operating margin of CONMED Corporation is 10.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at CONMED Corporation (CNMD)?

Revenue at CONMED Corporation is growing −1.3% versus a year earlier (3y avg +9.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at CONMED Corporation (CNMD)?

Earnings per share at CONMED Corporation are growing +137% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does CONMED Corporation (CNMD) carry?

The net debt of CONMED Corporation is $794M (fiscal year 2025, ≈ 5.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch CONMED Corporation in the live analysis

One click puts CONMED Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.